1, 25 Dihydroxyvitamin D3 uptake is localized at caveolae and requires caveolar function

Journal of Biomedical Nanotechnology

Volumn 9, Issue 10, 2013, Pages 1707-1715

  Schaefer, Rachel J ^a   Bonor, Jeremy C ^a   Joglekar, Madhura S ^a   Van Golen, Kenneth L ^a   Nohe, Anja G ^a  

^a UNIVERSITY OF DELAWARE   (United States)

Author keywords

Calcitriol; Caveolae; Nanoparticles; Quantum dots; Vitamin D

Indexed keywords

CELLS; CYTOLOGY; DISEASES; MOLECULAR BIOLOGY; NANOCRYSTALS; NANOPARTICLES; PROBES; SEMICONDUCTOR QUANTUM DOTS; VITAMINS;

1 ,25-DIHYDROXYVITAMIN D3; CALCITRIOL; CAVEOLAE; INFLAMMATORY BREAST CANCERS; MEDIATED ACTIVITIES; THERAPEUTIC EFFECTS; VITAMIN D RECEPTOR; VITAMIN-D;

CELL SIGNALING;

CALCITRIOL; QUANTUM DOT; VITAMIN D RECEPTOR;

ARTICLE; BREAST CANCER CELL LINE; CAVEOLA; CELL FUNCTION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENDOCYTOSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATORY BREAST CANCER; INTRACELLULAR SIGNALING; LUCIFERASE ASSAY; MEMBRANE DAMAGE; BREAST TUMOR; METABOLISM; TUMOR CELL LINE; ULTRASTRUCTURE;

BREAST NEOPLASMS; CALCITRIOL; CAVEOLAE; CELL LINE, TUMOR; ENDOCYTOSIS; HUMANS;

EID: 84902013603     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2013.1662     Document Type: Article

References (34)

1. M. Haroon and M. J. Regan, Vitamin D deficiency: The time to ignore it has passed. Int. J. Rheum. Dis. 13, 318 (2010).
2. B. Lehmann and M. Meurer, Vitamin D metabolism. Dermatol. Ther. Delivered by Publishing Technology IP: 203.56.241.128 On: Sat,Copyright: American 23, 2 (2010).
3. J. S. Adams and M. Hewison, Update in vitamin D. J. Clin. Endocrinol. Metab. 95, 471 (2010).
4. C. Pierrot-Deseilligny and J. C. Souberbielle, Widespread vitamin D insufficiency: A new challenge for primary prevention, with particular reference to multiple sclerosis. Presse Med. 40, 349 (2011).
5. P. Tuohimaa, T. Keisala, A. Minasyan, J. Cachat, and A. Kalueff, Vitamin D, nervous system and aging. Psychoneuroendocrinology 34, S278 (2009).
6. A. V. Krishnan and D. Feldman, Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D. Annu. Rev. Pharmacol. Toxicol. 51, 311 (2011).
7. R. L. Hillyer, P. Sirinvasin, M. Joglekar, R. A. Sikes, K. L. Van Golen, and A. Nohe, Differential effects of vitamin D treatment on inflammatory and non-inflammatory breast cancer cell lines. Clin. Exp. Metastasis 29, 971 (2012).
8. H. Dushkin and M. Cristofanilli, Inflammatory breast cancer. J. Natl. Compr. Canc. Netw. 9, 233 (2011).
9. F. M. Robertson, M. Bondy, W. Yang, H. Yamauchi, S. Wiggins, S. Kamrudin, S. Krishnamurthy, H. Le-Petross, L. Bidaut, A. N. Player, S. H. Barsky, W. A. Woodward, T. Buchholz, A. Lucci, N. T. Ueno, and M. Cristofanilli, Inflammatory breast cancer: The disease, the biology, the treatment. CA. Cancer J. Clin. 60, 351 (2010).
10. J. Bonor, R. Schaefer, N. Menegazzo, K. Booksh, and A. Nohe, Design of 1, 25 Dihydroxyvitamin D3 Coupled Quantum Dots, a Novel Imaging Tool. J. Nanosci. Nanotechnol. 12, 2185 (2012).
11. D. D. Bikle, Vitamin D: An ancient hormone. Exp. Dermatol. 20, 7 (2010).
12. C. L. Richard, M. C. Farach-Carson, B. Rohe, I. Nemere, and K. A. Meckling, Involvement of 1, 25D3-MARRS (membrane associated, rapid response steroid-binding), a novel vitamin D receptor, in growth inhibition of breast cancer cells. Exp. Cell. Res. 316, 695 (2010).
13. K. Tudpor, J. Teerapornpuntakit, W. Jantarajit, N. Krishnamra, and N. Charoenphandhu, 1, 25-dihydroxyvitamin D(3) rapidly stimulates the solvent drag-induced paracellular calcium transport in the duodenum of female rats. J. Physiol. Sci. 58, 297 (2008).
14. M. R. Haussler, P. W. Jurutka, M. Mizwicki, and A. W. Norman, Vitamin D receptor (VDR)-mediated actions of 1 alpha, 25(OH)(2)vitamin D(3): Genomic and non-genomic mechanisms. Best Pract. Res. Clin. Endocrinol. Metab. 25, 543 (2011).
15. T. E. Willnow and A. Nykjaer, Cellular uptake of steroid carrier proteins-mechanisms and implications. Mol. Cell. Endocrinol. 316, 93 (2009).
16. P. Lefebvre, Y. Benomar, and B. Staels, Retinoid X receptors: Common heterodimerization partners with distinct functions. Trends Endocrinol Metab. 21, 676 (2010).
17. T. S. Lisse, T. Liu, M. Irmler, J. Beckers, H. Chen, J. S. Adams, and M. Hewison, Gene targeting by the vitamin D response element binding protein reveals a role for vitamin D in osteoblast mTOR signaling. FASEB J. 25, 937 (2011).
18. J. M. Valdivielso, The physiology of vitamin D receptor activation. Contrib Nephrol. 163, 206 (2009).
19. S. S. Jensen, M. W. Madsen, J. Lukas, L. Binderup, and J. Bartek, Inhibitory effects of 1alpha, 25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery. Mol. Endocrinol. 15, 1370 (2001).
20. K. Sandvig, S. Pust, T. Skotland, and B. van Deurs, Clathrinindependent endocytosis: Mechanisms and function. Curr. Opin. Cell Biol., 23, 413 (2011).
21. A. L. Kiss and E. Botos, Endocytosis via caveolae: Alternative pathway with distinct cellular compartments to avoid lysosomal degradation?, J. Cell. Mol. Med. 13, 1228 (2009).
22. S. Staubach and F. G. Hanisch, Lipid rafts: Signaling and sorting platforms of cells and their roles in cancer. Expert Rev. Proteomics 8, 263 (2011).
23. K. Miyawaki-Shimizu, D. Predescu, J. Shimizu, M. Broman, S. Predescu, and A. B. Malik, siRNA-induced caveolin-1 knockdown in mice increases lung vascular permeability via the junctional pathway. Am. J. Physiol. Lung. Cell. Mol. Physiol. 290, L405 (2006).
24. S. K Rodal, G. Skretting, O. Garred, F. Vilhardt, B. van Deurs, and K. Sandvig, Extraction of cholesterol with methyl-beta-cyclodextrin perturbs formation of clathrin-coated endocytic vesicles. Mol. Biol. Cell. 10, 961 (1999).
25. R. L. Boland, VDR activation of intracellular signaling pathways in skeletal muscle. Mol. Cell. Endocrinol. 347, 11 (2011).
26. C. Buitrago and R. Boland, Caveolae and caveolin-1 are implicated in 1 alpha, 25(OH)2-vitamin D3-dependent modulation of Src, MAPK cascades and VDR localization in skeletal muscle cells. J. Steroid. Biochem. Mol. Biol. 121, 169 (2010).
27. F. Pancotti, L. Roncuzzi, M. Maggiolini, and A. Gasperi-Campani, Caveolin-1 silencing arrests the proliferation of metastatic lung cancer cells through the inhibition of STAT3 signaling. Cell Signal. 24, 1390 (2012).
28. L. Masuelli, A. Budillon, L. Marzocchella, M. A. Mrozek, D. Vitolo, E. Di Gennaro, S. Losito, P. Sale, F. Longo, F. Ionna, F. Lista, R. Muraro, A. Modesti, and R. Bei, Caveolin-1 overexpression is associated with simultaneous abnormal expression of the E-cadherin/alpha-beta catenins complex and multiple ErbB receptors and with lymph nodes metastasis in head and neck squamous cell carcinomas. J. Cell. Physiol. 227, 3344 (2011).
29. S. R. Kuo, S. A. Tahir, S. Park, T. C. Thompson, S. Coffield, A. E. Frankel, and J. S. Liu, Anti-caveolin-1 Antibodies As Anti-Prostate Cancer Therapeutics. Hybridoma (Larchmt) 31, 77 (2012).
30. K. N. Wu, M. Queenan, J. R. Brody, M. Potoczek, F. Sotgia, M. P. Lisanti, and A. K. Witkiewicz, Loss of stromal caveolin-1 expression in malignant melanoma metastases predicts poor survival. Cell. Cycle. 10, 4250 (2011).
31. E. K. Sloan, K. L. Stanley, and R. L. Anderson, Caveolin-1 inhibits breast cancer growth and metastasis. Oncogene 23, 7893 (2004).
32. M. N. Aoki, M. K. Amarante, J. M. Oda, and M. A. Watanabe, Caveolin involvement and modulation in breast cancer. Mini Rev. Med. Chem. 11, 1143 (2011).
33. G. G. Van den Eynden, S. J. Van Laere, I. Van der Auwera, S. D. Merajver, E. A. Van Marck, P. van Dam, P. B. Vermeulen, L. Y. Dirix, and K. L. van Golen, Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer. Breast Cancer Res. Treat., 95, 219 (2006).
34. S. V. Costes, D. Daelemans, E. H. Cho, Z. Dobbin, G. Pavlakis, and S. Lockett, Automatic and quantitative measurement of proteinprotein colocalization in live cells. Biophys. J. 86, 3993 (2004).